Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte hier.

November 19th 2020 – Hennigsdorf/Berlin

COVID-19: Despite the prospect of vaccines, tests are the tool of choice


  • Virologists and epidemiologists call for continuous testing to contain the pandemic

  • The DiagnostikNet-BB works on many levels of the test chain

  • IMDB develops new project family for comprehensive COVID-19 diagnostics

Despite the prospect of vaccine availability in the near future: For virologists and epidemiologists there is no way around consistent testing to effectively contain the SARS-CoV-2 pandemic. The members of the DiagnostikNet-BB are active in this context, for example with

  • Test offers for members

  • validated sample and reference material

  • Basic components for PCR tests, enzymes primers and antibodies

  • new tests in different formats

The Institute for Molecular Diagnostics and Bioanalytics (IMDB) bundles and complements these offers as a provider of individual laboratory diagnostic services in the DiagnostikNet-BB. This creates synergies and accelerates innovation and product development.
With its newly launched BMBF-funded project family, the IMDB sheds light on all aspects of SARS-CoV-2/COVID-19 diagnostics:

  • VALIDATE-Dx: assorts samples to form a cohort, which is backed by a complete anamnesis. Results of studies conducted with these samples are summarized and allow a comprehensive view of the disease process from genome to symptom.

  • PEPTIDE-Dx: provides individual epitope patterns of patients from different stages of the disease.

  • COMMUNICATE-Dx: systematically establishes digital contact with health authorities.

  • EPI-Dx: studies genomic variants of patient and virus.

  • TRAVEL-Dx: develops accelerated access to nucleic acid analysis as a PCR replacement for on-site diagnostics.

  • BEAD-Dx: creates the technological basis to correlate antibody data with autoimmune parameters.

  • DIRECT-Dx: investigates new ways to increase the sensitivity of antigen tests.

All projects are equipped with the VALIDATE-Dx cohort to generate valuable data for research and development of individualized test and therapy strategies. These are needed because Covid-19 is also a disease whose cure requires individual treatment methods.
You are welcome to visit our joint booth at medica.diagnostiknet-bb.de
Let me discover all Corona Innovations

Information

Prof. Jörg-M. Hollidt | Dr. Robert Lange | Prof. Frank F. Bier

Vorstand DiagnostikNet-BB

Veltener Str. 12 | 16761 Hennigsdorf bei Berlin

T +49 (0) 3302 23091-58 | Mobil +49 (0) 172-162 31 88

info@diagnostiknet-bb.de 

www.diagnostiknet-bb.de

About DiagnostikNet|BB

DiagnostikNet|BB (Netzwerk Diagnostik Berlin-Brandenburg e.V.) was founded in 2007 and combines the interests of highly innovative medium-sized companies and internationally renowned research institutes from all areas of in-vitro diagnostics in Berlin-Brandenburg and eight other German states as well as from Switzerland and France. The network represents a total of more than 6,000 employees and an annual turnover of more than 300 million euros.

If you wish to not receive this e-mail (to: yvonne.kuechler@berlin-partner.de) anymore, you can opt out here.

 

DiagnostikNet-BB e.V.
Hannes Thonagel
Veltener Str. 12
16761 Hennigsdorf/Berlin
Germany

Tel. +49 3302 23091-60
h.thonagel@diagnostiknet-bb.de
Board: Prof. Dr. Jörg-M. Hollidt, Dr. Robert Lange, Prof. Dr. Frank F. Bier
Register: VR 4183 NP
Tax ID: 053/142/02475
www.diagnostiknet-bb.de